Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome
NCT05087589
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Primary Sjögren's Syndrome
Interventions
DRUG:
Tofacitinib
Sponsor
Peking University People's Hospital